Compare Stocks: RZLT, SNDX, IMCR, and XNCR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMCR Immunocore	$36.88 +1.7%	$32.97	$27.56 ▼ $40.71	$1.88B	0.74	432,604 shs	329,451 shs
RZLT Rezolute	$5.09 +9.2%	$4.84	$1.07 ▼ $11.46	$490.13M	0.58	1.09 million shs	6.50 million shs
SNDX Syndax Pharmaceuticals	$19.65 -0.5%	$20.82	$12.99 ▼ $25.59	$1.74B	0.4	1.36 million shs	1.70 million shs
XNCR Xencor	$27.80 +3.0%	$18.22	$7.50 ▼ $28.16	$2.07B	0.85	1.16 million shs	753,067 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMCR Immunocore	0.00%	+7.80%	+3.86%	+27.92%	+13.51%
RZLT Rezolute	0.00%	+10.65%	-4.14%	+56.62%	-23.57%
SNDX Syndax Pharmaceuticals	0.00%	-0.96%	-7.36%	-1.45%	+24.84%
XNCR Xencor	0.00%	+19.11%	+42.35%	+145.80%	+270.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMCR Immunocore	$36.88 +1.7%	$32.97	$27.56 ▼ $40.71	$1.88B	0.74	432,604 shs	329,451 shs
RZLT Rezolute	$5.09 +9.2%	$4.84	$1.07 ▼ $11.46	$490.13M	0.58	1.09 million shs	6.50 million shs
SNDX Syndax Pharmaceuticals	$19.65 -0.5%	$20.82	$12.99 ▼ $25.59	$1.74B	0.4	1.36 million shs	1.70 million shs
XNCR Xencor	$27.80 +3.0%	$18.22	$7.50 ▼ $28.16	$2.07B	0.85	1.16 million shs	753,067 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMCR Immunocore	0.00%	+7.80%	+3.86%	+27.92%	+13.51%
RZLT Rezolute	0.00%	+10.65%	-4.14%	+56.62%	-23.57%
SNDX Syndax Pharmaceuticals	0.00%	-0.96%	-7.36%	-1.45%	+24.84%
XNCR Xencor	0.00%	+19.11%	+42.35%	+145.80%	+270.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMCR Immunocore	2.58	Moderate Buy	$56.38	52.86% Upside
RZLT Rezolute	2.58	Moderate Buy	$9.38	84.18% Upside
SNDX Syndax Pharmaceuticals	2.85	Moderate Buy	$41.55	111.43% Upside
XNCR Xencor	2.44	Hold	$24.86	-10.59% Downside

Current Analyst Ratings Breakdown

Latest RZLT, SNDX, IMCR, and XNCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$37.00 ➝ $33.00
8/21/2026	IMCR Immunocore	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$50.00
8/14/2026	RZLT Rezolute	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
8/7/2026	IMCR Immunocore	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$43.00
8/6/2026	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$19.00 ➝ $20.00
8/6/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $30.00
8/6/2026	XNCR Xencor	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$43.00 ➝ $44.00
8/5/2026	SNDX Syndax Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	IMCR Immunocore	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMCR Immunocore	$400.02M	4.69	N/A	N/A	$8.25 per share	4.47
RZLT Rezolute	N/A	N/A	N/A	N/A	$1.86 per share	N/A
SNDX Syndax Pharmaceuticals	$252.25M	6.90	N/A	N/A	$0.17 per share	115.59
XNCR Xencor	$125.58M	16.46	N/A	N/A	$6.77 per share	4.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMCR Immunocore	-$35.51M	-$0.37	N/A	76.83	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
RZLT Rezolute	-$74.41M	-$0.82	N/A	N/A	N/A	N/A	-58.82%	-54.48%	9/16/2026 (Estimated)
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)
XNCR Xencor	-$91.92M	-$2.17	N/A	N/A	N/A	-155.59%	-28.66%	-20.38%	11/4/2026 (Estimated)

Latest RZLT, SNDX, IMCR, and XNCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/16/2026	Q4 2026	RZLT Rezolute	-$0.13	N/A	N/A	N/A	N/A	N/A
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A
8/5/2026	Q2 2026	XNCR Xencor	-$0.8015	-$0.29	+$0.5115	-$0.29	$18.89 million	$51.22 million
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMCR Immunocore	0.94	4.47	4.44
RZLT Rezolute	N/A	15.84	15.84
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44
XNCR Xencor	N/A	6.39	6.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMCR Immunocore	84.50%
RZLT Rezolute	82.97%
SNDX Syndax Pharmaceuticals	N/A
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
IMCR Immunocore	10.10%
RZLT Rezolute	14.78%
SNDX Syndax Pharmaceuticals	4.80%
XNCR Xencor	5.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMCR Immunocore	320	50.87 million	45.73 million	Optionable
RZLT Rezolute	40	96.29 million	82.06 million	Optionable
SNDX Syndax Pharmaceuticals	110	88.61 million	84.36 million	Optionable
XNCR Xencor	280	74.35 million	70.58 million	Optionable

RZLT, SNDX, IMCR, and XNCR Headlines

Recent News About These Companies

103,736 Shares in Xencor, Inc. $XNCR Bought by DCF Advisers LLC

August 20 at 4:16 AM | marketbeat.com

Xencor (NASDAQ:XNCR) Hits A Fresh High: What Comes Next?

August 18, 2026 | kalkinemedia.comK

Xencor (NASDAQ:XNCR) Sets New 52-Week High - Should You Buy?

August 18, 2026 | marketbeat.com

Johnson & Johnson Purchases New Shares in Xencor, Inc. $XNCR

August 16, 2026 | marketbeat.com

Xencor, Inc. (XNCR) Stock Major Holders - Yahoo Finance

August 12, 2026 | finance.yahoo.com

Xencor (NASDAQ:XNCR) Hits New 1-Year High - Here's What Happened

August 12, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Alpha Teknova (TKNO) and Solventum Corporation (SOLV)

August 11, 2026 | theglobeandmail.com

Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Xencor: Q2 Earnings Snapshot

August 7, 2026 | sfgate.com

RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)

August 7, 2026 | theglobeandmail.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

August 7, 2026 | marketbeat.com

Xencor Reports Second Quarter 2026 Financial Results

August 7, 2026 | aol.comA

Xencor (NASDAQ:XNCR) Price Target Raised to $30.00

August 6, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings

August 6, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Price Target Raised to $44.00 at Cantor Fitzgerald

August 6, 2026 | marketbeat.com

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

August 5, 2026 | zacks.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS

August 5, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading Down 3.9% - Here's Why

August 3, 2026 | marketbeat.com

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

August 3, 2026 | tipranks.com

Xencor (NASDAQ:XNCR) Reaches New 1-Year High - Should You Buy?

July 30, 2026 | marketbeat.com

Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR)

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT, SNDX, IMCR, and XNCR Company Descriptions

Immunocore NASDAQ:IMCR

$36.88 +0.60 (+1.65%)

As of 08/21/2026 04:00 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Rezolute NASDAQ:RZLT

$5.09 +0.43 (+9.23%)

As of 08/21/2026 04:00 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Syndax Pharmaceuticals NASDAQ:SNDX

$19.65 -0.10 (-0.51%)

As of 08/21/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Xencor NASDAQ:XNCR

$27.80 +0.80 (+2.96%)

As of 08/21/2026 04:00 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RZLT, SNDX, IMCR, and XNCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RZLT, SNDX, IMCR, and XNCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RZLT, SNDX, IMCR, and XNCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT, SNDX, IMCR, and XNCR Company Descriptions

Immunocore NASDAQ:IMCR

Rezolute NASDAQ:RZLT

Syndax Pharmaceuticals NASDAQ:SNDX

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RZLT, SNDX, IMCR, and XNCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RZLT, SNDX, IMCR, and XNCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RZLT, SNDX, IMCR, and XNCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT, SNDX, IMCR, and XNCR Company Descriptions

Immunocore NASDAQ:IMCR

Rezolute NASDAQ:RZLT

Syndax Pharmaceuticals NASDAQ:SNDX

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools